Ernexa Therapeutics (ERNAW) Invested Capital (2013 - 2026)

Ernexa Therapeutics' (ERNAW) quarterly Invested Capital came in at $41000.0 in Q1 2026, little changed on a QoQ basis from $41000.0 in Q4 2025.

Analysis

Ernexa Therapeutics (ERNAW) Invested Capital (2013 - 2026) Analysis & Trends

Ernexa Therapeutics (ERNAW) has 14 years of Invested Capital data on file, last reported at $41000.0 in Q1 2026.

Quarterly Invested Capital changed N/A year-over-year to $41000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164000.0 (changed N/A YoY) and the FY2025 annual result came in at $41000.0, changed N/A from the prior year.
Invested Capital held at $41000.0 in Q1 2026, from $41000.0 in the prior quarter.
In the past five years, Invested Capital ranged from a high of $1.8 million in Q4 2022 to a low of $41000.0 in Q2 2025.
A 4-year average of $610666.7 and a median of $41000.0 in 2025 frame the typical range for Invested Capital.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Ernexa Therapeutics	67,312.70	67,312.70	-	-

Historic Data

Download Data